Increased serum circulating asprosin levels in children with obesity

Silistre, Eda Sünnetçi; Hatipoğl, Halil Uğur

doi:10.1111/ped.14176

Cited by 48 publications

(40 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Wang et al showed that obese children exhibited high levels of asprosin when compared to controls, associating with insulin resistance [ 23 ]. A recent study in Turkish population found similar results [ 44 ]. Intriguingly, there is dramatic discrepancy in circulating levels of asprosin among studies.…”

Section: Discussionsupporting

confidence: 76%

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

et al. 2021

View full text Add to dashboard Cite

Background Coronary artery disease (CAD) is considered as a multi-faceted chronic inflammatory disease involving reduced blood supply to the myocardium as a result of accumulating lipids in the atrial walls. Visceral adiposity with disrupted release of adipokines play a key role in its pathogenesis. Asprosin is a newly identified fasting-induced glucogenic adipokine that has been related with metabolic disorders such as type II diabetes mellitus and polycystic ovary syndrome. The preset study sought to assess circulating asprosin in context of CAD. Methods In this study, serum levels of asprosin were determined in 88 CAD patients and 88 non-CAD healthy controls. Serum IL-6, TNF-α, asprosin and adiponectin were assessed using ELISA kits. Results: Serum asprosin was found to be higher in CAD patients when compared to non-CAD subjects (7.84 ± 2.08 versus 5.02 ± 1.29 μg/mL, p < 0.001). Similarly, serum TNF-α, and IL-6 elevated in CAD group significantly (p < 0.001). However, circulating adiponectin diminished in CAD group when compared with non-CAD subjects (p < 0.001). Moreover, serum asprosin levels directly correlated with BMI, FBG, HOMA-IR, TG and TC. Logistic regression analyses showed that asprosin levels were associated with increased risk of developing CAD (odds ratio: 3.01, 95% CI: 2.16, 4.20 and p < 0.001), after adjusting for potential confounders (age, sex and BMI). Conclusions The present study findings suggested a possible relation of serum asprosin with the pathogenesis of CAD, in particular through insulin resistance and dyslipidemia.

show abstract

Section: Discussionsupporting

confidence: 76%

Serum levels of Asprosin in patients diagnosed with coronary artery disease (CAD): a case-control study

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Research performed in children reveal controversial results. While Silistre et al as well as Wang et al obtained higher levels of asprosin in children with obesity 19 , 20 as expected, Long et al observed a decrease in asprosin levels in children with obesity when compared with the normal weight control group, but no elucidation was given for these results. 21 …”

Section: Asprosin and Obesity Managementmentioning

confidence: 88%

A state of the art review on the novel mediator asprosin in the metabolic syndrome

Luís

Fernandes

Soares

et al. 2020

Porto Biomedical Journal

View full text Add to dashboard Cite

Metabolic syndrome is a complex and heterogeneous pathology characterized by a cluster of biochemical, clinical, and metabolic factors that came together in raising the risk of cardiovascular diseases, type 2 diabetes mellitus, and all-cause mortality. Some of these features are well defined in this syndrome like: obesity, inflammation, hypertension, insulin resistance, atherosclerotic dyslipidemias, endothelial dysfunction, and inflammation. This circuit is intermediated by a complex network of hormones, cytokines, transcription factors, and adipokines, among others. Some like leptin, adiponectin, Plasminogen activator inhibitor-1, interleukin-6, Tumor necrosis factor, and their influence on the metabolic syndrome are well described in the literature and new players are described continuously. One novel player was described in 2016 by Romere et al as a fasting-induced glycogenic protein hormone named asprosin. In order to perform a state-of-the-art, nonsystematic review of asprosin, a study of the available literature was carried out in the main database (Pubmed) and the results were studied and correlated to better understand the mechanism of action of this hormone. Asprosin is not only associated with the metabolic syndrome features like glucose and lipid metabolism, insulin resistance, obesity and inflammation but also in other pathologies metabolic syndrome related like diabetic retinopathy, polycystic ovary syndrome and anorexia nervosa. A limited number of pathways were already unveiled although much more research is needed to better understand the therapeutical potential of asprosin in the metabolic syndrome.

show abstract

“…Currently, only little data regarding asprosin levels in pregnant women or children are available. So far, two clinical studies addressed maternal and newborn asprosin levels [3,26] whereas three studies examined serum asprosin in overweight and obese children [16,21,23].…”

Section: Introductionmentioning

confidence: 99%

“…The study did not detect any other significant correlations between asprosin and additional metabolic factors. The authors report asprosin as a marker for childhood obesity and conclude "Further studies are needed to demonstrate the role of asprosin in the etiology of childhood obesity, as well as other diseases that might be associated with effects of asprosin" [21].…”

Section: Introductionmentioning

confidence: 99%